Healthcare provider profile · identity verified

Ivan Yee, D.O.

Internal Medicine · ORANGE, CA · NPI 1154653640

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	474	170
Amlodipine Besylate	Amlodipine Besylate	262	92
Losartan Potassium	Losartan Potassium	203	72
Levothyroxine Sodium	Levothyroxine Sodium	145	46
Simvastatin	Simvastatin	141	44
Azelastine Hcl	Azelastine Hcl	131	60
Lisinopril	Lisinopril	131	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	127	40
Pantoprazole Sodium	Pantoprazole Sodium	112	41
Meloxicam	Meloxicam	107	57
Tamsulosin Hcl	Tamsulosin Hcl	107	39
Atenolol	Atenolol	101	36
Rosuvastatin Calcium	Rosuvastatin Calcium	99	36
Terazosin Hcl	Terazosin Hcl	92	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	90	34
Metoprolol Tartrate	Metoprolol Tartrate	87	28
Finasteride	Finasteride	84	30
Gabapentin	Gabapentin	84	28
Metformin Hcl	Metformin Hcl	80	29
Allopurinol	Allopurinol	79	22
Glipizide	Glipizide	79	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	73	21
Metformin Hcl Er	Metformin Hcl	72	26
Hydrochlorothiazide	Hydrochlorothiazide	69	25
Potassium Chloride	Potassium Chloride	65	21
Metoprolol Succinate	Metoprolol Succinate	61	19
Albuterol Sulfate Hfa	Albuterol Sulfate	58	25
Sertraline Hcl	Sertraline Hcl	54	18
Triamcinolone Acetonide	Triamcinolone Acetonide	50	28
Furosemide	Furosemide	48	21
Pradaxa	Dabigatran Etexilate Mesylate	48	19
Alendronate Sodium	Alendronate Sodium	46	13
Donepezil Hcl	Donepezil Hcl	44	suppressed
Montelukast Sodium	Montelukast Sodium	43	17
Trazodone Hcl	Trazodone Hcl	42	12
Carvedilol	Carvedilol	41	15
Prednisone	Prednisone	39	24
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	38	38
Jardiance	Empagliflozin	37	13
Tramadol Hcl	Tramadol Hcl	37	suppressed
Omeprazole	Omeprazole	35	18
Pravastatin Sodium	Pravastatin Sodium	35	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	33	17
Ibuprofen	Ibuprofen	29	suppressed
Acyclovir	Acyclovir	28	12
Eliquis	Apixaban	28	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	11
Doxycycline Monohydrate	Doxycycline Monohydrate	25	24
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Famotidine	Famotidine	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	20
Glipizide-Metformin	Glipizide/Metformin Hcl	22	suppressed
Ciclopirox	Ciclopirox	21	11
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	20	11
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	20	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	18
Colchicine	Colchicine	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Azithromycin	Azithromycin	17	17
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Amoxicillin	Amoxicillin	16	13
Nystatin	Nystatin	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Estradiol	Estradiol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error